+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

New Targeting in The Reversal of Resistant Glioblastomas. Cancer Sensitizing Agents for Chemotherapy

  • ID: 5130635
  • Book
  • January 2021
  • 309 Pages
  • Elsevier Science and Technology
1 of 3
New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.
  • Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies
  • Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed
  • Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma
Note: Product cover images may vary from those shown
2 of 3

1. Current status of recurrent glioblastoma therapies 2. Imaging of glioblastoma recurrence 3. Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma 4. The intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies 5. Targeting Glioma Stem Cell Metabolism to Enhance Therapy Responses and Minimize Resistance 6. TBA Pros and cos of immunotherapy 7. TBA Glioblastoma resistance and convection therapy 8. TBA Sensitization of resistant GBM to radiation

Note: Product cover images may vary from those shown
3 of 3
Arbab, Ali Syed
Ali Syed Arbab, MD PHD, is Leader of Tumor Angiogenesis Initiative and Director, Core Imaging Facilities for Small Animals, both at Augusta University. Dr. Arbab's laboratory is devoted to determining the mechanisms of therapy resistance by focusing on the involvement of bone marrow derived cells in modulating the tumor microenvironment and initiating tumor neovascularization in glioblastoma models. To understand the involvement of bone marrow cells in developing resistance to antiangiogenic therapies (AAT), his group has developed chimeric animal models where bone marrow of the recipient animal is replaced with GFP+ bone marrow. Dr. Arbab's group documented that tumor-recruited bone marrow cells are a predominantly heterogeneous myeloid cell population that can predict therapeutic response in cancer, and they are using several strategies to target bone marrow or tumor-promoting myeloid cells to potentiate the anti-tumor effect of FDA-approved drugs in preclinical models of glioblastoma.
Note: Product cover images may vary from those shown
Adroll
adroll